PubMed

Lifetime costs of complications resulting from type 2 diabetes in the U.S.

Caro JJ, Ward AJ, O'Brien JA.

Diabetes Care. 2002 Mar;25(3):476-81.PMID: 11874933 [PubMed - indexed for MEDLINE]Related articlesFree article

Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.

Salas M, Ward A, Caro J.

Clin Ther. 2002 Oct;24(10):1690-705.PMID: 12462297 [PubMed - indexed for MEDLINE]Related articles

Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.

O'Brien JA, Patrick AR, Caro J.

Clin Ther. 2003 Mar;25(3):1017-38.PMID: 12852716 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.

Brändle M, Azoulay M, Greiner RA.

Int J Clin Pharmacol Ther. 2007 Apr;45(4):203-20.PMID: 17474539 [PubMed - indexed for MEDLINE]Related articles

Direct medical costs of complications resulting from type 2 diabetes in the U.S.

O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ.

Diabetes Care. 1998 Jul;21(7):1122-8.PMID: 9653606 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost of managing complications resulting from type 2 diabetes mellitus in Canada.

O'Brien JA, Patrick AR, Caro JJ.

BMC Health Serv Res. 2003 Mar 21;3(1):7.PMID: 12659641 [PubMed - indexed for MEDLINE]Related articlesFree article

Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.

Gandra SR, Lawrence LW, Parasuraman BM, Darin RM, Sherman JJ, Wall JL.

J Manag Care Pharm. 2006 Sep;12(7):546-54.PMID: 16981800 [PubMed - indexed for MEDLINE]Related articlesFree article

Assessing the impact of complications on the costs of Type II diabetes.

Williams R, Van Gaal L, Lucioni C; CODE-2 Advisory Board.

Diabetologia. 2002 Jul;45(7):S13-7. Epub 2002 Jun 12.PMID: 12136406 [PubMed - indexed for MEDLINE]Related articles

Glycemic control and the risk of multiple microvascular diabetic complications.

Schellhase KG, Koepsell TD, Weiss NS.

Fam Med. 2005 Feb;37(2):125-30.PMID: 15690253 [PubMed - indexed for MEDLINE]Related articlesFree article

The health care costs of diabetic peripheral neuropathy in the US.

Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA.

Diabetes Care. 2003 Jun;26(6):1790-5.PMID: 12766111 [PubMed - indexed for MEDLINE]Related articlesFree article

The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).

Clarke P, Gray A, Legood R, Briggs A, Holman R.

Diabet Med. 2003 Jun;20(6):442-50.PMID: 12786677 [PubMed - indexed for MEDLINE]Related articles

Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the "diabetes mellitus model".

Maxion-Bergemann S, Huppertz E, Jacobs LD, Müller E, Walleser S.

Int J Clin Pharmacol Ther. 2005 Jun;43(6):271-81.PMID: 15968884 [PubMed - indexed for MEDLINE]Related articles

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM; RENAAL Investigators.

Pharmacoeconomics. 2006;24(6):549-58.PMID: 16761903 [PubMed - indexed for MEDLINE]Related articles

Potential short-term economic benefits of improved glycemic control: a managed care perspective.

Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R.

Diabetes Care. 2001 Jan;24(1):51-5.PMID: 11194241 [PubMed - indexed for MEDLINE]Related articlesFree article

[Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study]

Liebl A, Spannheimer A, Reitberger U, Görtz A.

Med Klin (Munich). 2002 Dec 15;97(12):713-9. German. PMID: 12491064 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

CDC Diabetes Cost-effectiveness Group.

JAMA. 2002 May 15;287(19):2542-51.PMID: 12020335 [PubMed - indexed for MEDLINE]Related articlesFree article

Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4).

Martin S, Schramm W, Schneider B, Neeser K, Weber C, Lodwig V, Heinemann L, Scherbaum WA, Kolb H.

Exp Clin Endocrinol Diabetes. 2007 Sep;115(8):495-501.PMID: 17853332 [PubMed - indexed for MEDLINE]Related articles

Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.

Grima DT, Thompson MF, Sauriol L.

Pharmacoeconomics. 2007;25(3):253-66.PMID: 17335310 [PubMed - indexed for MEDLINE]Related articles

[Disease management program (DMP) diabetes mellitus: simulation of therapeutic results of different guidelines. A new diabetes mellitus model (DMM)]

Hauner H, Maxion-Bergemann S, Müller E, Schulz M, Huppertz E, Bergemann R.

Dtsch Med Wochenschr. 2003 May 23;128(21):1167-72. German. PMID: 12761689 [PubMed - indexed for MEDLINE]Related articles

Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets.

Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S.

Int J Clin Pract. 2006 Sep;60(9):1138-45. Review.PMID: 16939559 [PubMed - indexed for MEDLINE]Related articles